Waldenstrom Macroglobulinemia research hub
10 indexed studies · 6 currently recruiting
- active not recruitingPHASE2
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
This study looks at a new drug, Sonrotoclax, for adults with Waldenström Macroglobulinemia. It tests the drug alone for those whose previous treatments weren't enough, and with another drug, Zanubrutinib, for those who haven't had treatment before. The aim is to see if it's safe and effective.
United States · Australia · Canada - recruitingPHASE1, PHASE2
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
This study is testing a new medicine called BGB-16673 for people with certain types of B-cell cancers, like lymphoma or chronic leukaemia. It aims to find the right dose and see how well it works and if it's safe. It's an early-stage trial.
United States · Australia · Brazil - recruitingPHASE3
A Long-term Extension Study of PCI-32765 (Ibrutinib)
This study offers ongoing access to a drug called ibrutinib for people already using it for certain blood cancers and conditions, who are still benefiting. It also helps gather more long-term information on how safe and effective ibrutinib is.
United States · Argentina · Australia - active not recruitingPHASE2
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
This study looks at a new drug, Iopofosine I-131, for people with certain B-cell cancers like Waldenstrom, myeloma, or lymphoma, who haven't responded well to other treatments. It aims to see how safe and effective this new approach is.
United States · Australia · Brazil - not yet recruitingPHASE1
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
This study is testing a new drug, LY4152199, for people with certain types of B-cell lymphoma that have returned or not responded to previous treatments. Researchers want to find the best dose and see how safe and effective it is.
United States · Australia · Canada - active not recruitingPHASE2
Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia
This study is looking into a new treatment for Waldenström's Macroglobulinemia (WM), a type of blood cancer. It combines three medicines – Ibrutinib, Bortezomib, and Rituximab – to see if this chemotherapy-free approach works well and has fewer side effects in people newly diagnosed with WM.
Germany · Greece - recruitingPHASE2
Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia
This study is testing a new, chemotherapy-free treatment for Waldenström's macroglobulinemia (WM). It combines two drugs, Venetoclax and Rituximab, to see if they work better than traditional chemotherapy for people newly diagnosed with WM.
Germany · Greece - recruitingPHASE2, PHASE3
Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia
This study compares two treatments for a rare blood cancer called Waldenström's macroglobulinaemia. We're looking for better, gentler options than current treatments, hoping to improve health and quality of life for patients.
United Kingdom - recruitingPHASE1
Study of SGR-1505 in Mature B-Cell Neoplasms
This study is testing a new medicine called SGR-1505 for certain types of B-cell lymphoma. We want to find out if it's safe, what dose works best, and if it can help slow down the disease. It's for people whose treatment hasn't worked or stopped working.
United States · France · Italy - active not recruitingPHASE2
Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia
This study looks at combining two drugs, Carfilzomib and Ibrutinib, to treat Waldenström's Macroglobulinemia (WM). We want to see if this combination works better than Ibrutinib alone, especially for patients whose disease has certain genetic features. It's a Phase 2 trial.
Austria · Germany · Greece